We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RLMD market cap is 90.3M. The company's latest EPS is USD -3.2822 and P/E is -0.92.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -38.7M | -28.15M | -26.03M | -22.69M | -26.83M |
| Net Income | -37.95M | -26.32M | -25.3M | -22M | -25.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.27M | -60.84M | -125.7M | -161.25M | -103.7M |
| Net Income | -8.2M | -59.46M | -125.75M | -157.04M | -98.79M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 152.91M | 135.57M | 122.04M | 109.15M | 97.55M |
| Total Liabilities | 12.47M | 10.1M | 10.7M | 8.42M | 12.2M |
| Total Equity | 140.44M | 125.47M | 111.34M | 100.73M | 85.36M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 117.14M | 118.19M | 223.33M | 152.91M | 97.55M |
| Total Liabilities | 1.46M | 12.6M | 15.06M | 12.47M | 12.2M |
| Total Equity | 115.68M | 105.58M | 208.27M | 140.44M | 85.36M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -103.8M | -16.51M | -29.78M | -41.41M | -51.66M |
| Investing | 19.73M | 40M | 38.85M | 42.71M | 50.45M |
| Financing | 45.02M | N/A | N/A | N/A | -98k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.41M | -27.81M | -91.87M | -103.8M | -51.66M |
| Investing | -80.17M | -34.45M | -54.12M | 19.73M | 50.45M |
| Financing | 113.64M | 28.47M | 187.94M | 45.02M | -98k |
| Market Cap | 90.3M |
| Price to Earnings Ratio | -0.92 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 22.21 |
| Price to Book Ratio | 1.06 |
| Dividend Yield | - |
| Shares Outstanding | 30.1M |
| Average Volume (1 week) | 78.01k |
| Average Volume (1 Month) | 84.02k |
| 52 Week Change | 0.67% |
| 52 Week High | 7.2225 |
| 52 Week Low | 2.3601 |
| Spread (Intraday) | 0.36 (11.08%) |
| Company Name | Relmada Therapeutics Inc |
| Address |
50 west liberty street suite 880 reno, nevada 89501 |
| Website | https://www.relmada.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
